Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associate...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

GreedyM Aug. 19 at 2:12 PM

$PDSB is this turd really going red with Bio’s ripping?

0 · Reply

GreedyM Aug. 18 at 9:24 PM

$PDSB somebody doesn’t want this going up.

2 · Reply

FesertBoy Aug. 18 at 5:02 PM

$PDSB -30k for me. I’m out.

1 · Reply

KG1816 Aug. 18 at 2:47 PM

$PDSB what’s crazy is institutional ownership went up for Q2. Probably close to 0 now.

0 · Reply

Mr_Charlie Aug. 17 at 5:47 PM

$PDSB for when the announcement of bankruptcy?

1 · Reply

FesertBoy Aug. 17 at 2:57 PM

$PDSB well boys, start posting some loss porn at this point. Could’ve done so much fun shit with the money I lost on this POS

4 · Reply

k3vl4r Aug. 15 at 11:25 PM

$PDSB is down 44% from $9 to $5. Watching it for tomorrow’s close. https://app.k3vl4r.com/forecast/PDSB?utm_source=x&utm_medium=social&utm_campaign=signal&utm_content=PDSB #stocks #investing

0 · Reply

alphabetsop Aug. 15 at 5:42 PM

$PDSB looking forward to the announcement on the deals. do you really think PDS and its advisors didn’t expect the hammering? maybe 3M cash now in mid august. do you really think they spent time and money on shifting gears only to dilute to pennies in OTC with hopes of new strategy living another day. you will find out soon and be very happy imo.

2 · Reply

Mr_Charlie Aug. 15 at 10:12 AM

$PDSB $MREO now worth more than PDSB. Frank really fuc.... big time. He isn't even capable of coming out and apologise to shareholders. What a caracter!!

0 · Reply

RobotNC1 Aug. 15 at 1:15 AM

$PDSB I hit sell a when it was only a 30% drop. I got lucky. I really hope this comes back for everyone. Even some. Maybe it will rally soon.

0 · Reply

PDS Biotechnology reports Q2 EPS (18c), consensus (13c)

2026-08-17T07:27:37.000Z - 2 days ago

PDS Biotechnology price target lowered to $7 from $15 at H.C. Wainwright

Aug 13, 2026, 8:30 AM EDT - 6 days ago

PDS Biotech Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 7:00 AM EDT - 6 days ago

PDS Biotechnology Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

PDS Biotechnology Quarterly report: Q2 2026

Aug 11, 2026, 8:25 AM EDT - 8 days ago

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

Aug 10, 2026, 8:00 AM EDT - 9 days ago

PDS Biotechnology Transcript: AGM 2026

2026-07-10T20:35:12.000Z - 5 weeks ago

PDS Biotechnology registers to sell 13.32M shares of common stock for holders

Jul 10, 2026, 8:00 AM EDT - 5 weeks ago

PDS Biotechnology Registration statement: Registration filing

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

PDS Biotechnology Proxy statement: Proxy filing

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

PDS Biotechnology Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 3 months ago

PDS Biotechnology Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

PDS Biotechnology Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

PDS Biotechnology Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

May 6, 2026, 8:00 AM EDT - 3 months ago

PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results

Apr 24, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Registration statement: Registration filing

Apr 22, 2026, 7:00 AM EDT - 4 months ago

PDS Biotechnology Slides: Corporate presentation

2026-04-15T13:37:04.000Z - 4 months ago

PDS Biotechnology announces positive Phase 2 trial data for PDS01ADC

Apr 15, 2026, 8:45 AM EDT - 4 months ago

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Mar 30, 2026, 8:00 AM EDT - 5 months ago

PDS Biotechnology Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

PDS Biotechnology Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

PDS Biotechnology Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Mar 24, 2026, 4:05 PM EDT - 5 months ago

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

Feb 20, 2026, 8:30 AM EST - 6 months ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Jan 28, 2026, 8:45 AM EST - 7 months ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 7 months ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 7 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 9 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 9 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 8:00 AM EST - 9 months ago

PDS Biotechnology Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

PDS Biotechnology Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

PDS Biotechnology Earnings release: Q3 2025

Nov 13, 2025, 7:30 AM EST - 9 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 10 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 10 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 10 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 10 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 11 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Registration statement: Registration Filing

Aug 25, 2025, 8:30 AM EDT - 1 year ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 17, 2025, 12:00 PM EDT - 1 year ago

PDS Biotechnology Transcript: Status Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Registration statement: Registration Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Transcript: Study Update

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Press release: Study Update

May 22, 2025, 5:26 PM EDT - 1 year ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

May 21, 2025, 5:20 PM EDT - 1 year ago

PDS Biotechnology Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 1 year ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 23, 2025, 10:16 AM EDT - 1 year ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 2:30 PM EDT - 1 year ago

PDS Biotechnology Transcript: Life Sciences Virtual Investor Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings release: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 2 years ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 9, 2024, 8:00 AM EDT - 2 years ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

GreedyM Aug. 19 at 2:12 PM

$PDSB is this turd really going red with Bio’s ripping?

0 · Reply

GreedyM Aug. 18 at 9:24 PM

$PDSB somebody doesn’t want this going up.

2 · Reply

FesertBoy Aug. 18 at 5:02 PM

$PDSB -30k for me. I’m out.

1 · Reply

KG1816 Aug. 18 at 2:47 PM

$PDSB what’s crazy is institutional ownership went up for Q2. Probably close to 0 now.

0 · Reply

Mr_Charlie Aug. 17 at 5:47 PM

$PDSB for when the announcement of bankruptcy?

1 · Reply

FesertBoy Aug. 17 at 2:57 PM

$PDSB well boys, start posting some loss porn at this point. Could’ve done so much fun shit with the money I lost on this POS

4 · Reply

k3vl4r Aug. 15 at 11:25 PM

$PDSB is down 44% from $9 to $5. Watching it for tomorrow’s close. https://app.k3vl4r.com/forecast/PDSB?utm_source=x&utm_medium=social&utm_campaign=signal&utm_content=PDSB #stocks #investing

0 · Reply

alphabetsop Aug. 15 at 5:42 PM

2 · Reply

Mr_Charlie Aug. 15 at 10:12 AM

$PDSB $MREO now worth more than PDSB. Frank really fuc.... big time. He isn't even capable of coming out and apologise to shareholders. What a caracter!!

0 · Reply

RobotNC1 Aug. 15 at 1:15 AM

$PDSB I hit sell a when it was only a 30% drop. I got lucky. I really hope this comes back for everyone. Even some. Maybe it will rally soon.

0 · Reply

Fishman2001 Aug. 14 at 4:04 PM

$PDSB I demand the Board of Directors fire Frank.

1 · Reply

JohntyCT Aug. 14 at 2:32 PM

$PDSB the board of directors should fire Frank and appoint someone to sell the company, or its assets to the highest bidder. F-you Frank! Happy Friday!

0 · Reply

Kosmokrat Aug. 13 at 8:13 PM

$PDSB I wonder if $PDSB could just sell their PDS0101 asset completely to generate enough cash to fund the clinical trials for their PD0301? Or does anybody have any insight into the prospects of PDS0101? If it was actually losing the race to better drug candidates I could understand $PDSB's decision to deprioritize this asset.

1 · Reply

StocktwitsEarnings Aug. 13 at 7:51 PM

$PDSB Q2 '26 Earnings Results & Recap PDS Biotechnology Corporation reported a net loss of $9.8 million, or $0.18 per basic and diluted share, for the three months ended June 30, 2026, compared to $9.4 million in 2025.

0 · Reply

Libor_the_Bull Aug. 13 at 5:00 PM

$PDSB yea we all see that pin bar. would be nice to repeat so I can reenter

0 · Reply

Mr_Charlie Aug. 13 at 4:55 PM

$PDSB a bunch of silly Bulls think this company still can survive and thrive! Go get a proper job you stupid pumpers.

0 · Reply

JohntyCT Aug. 13 at 4:21 PM

$PDSB anybody have access this this report? I want some of what he is smoking!

2 · Reply

LabPsycho Aug. 13 at 3:12 PM

$PDSB IMO, pretty much telegraphed how they felt about shareholders long ago.

0 · Reply

Libor_the_Bull Aug. 13 at 3:11 PM

$PDSB kicked out by stop loss at 0.218 these stoploss raids are annoying. ah well.

0 · Reply

makesomemoneybro123 Aug. 13 at 3:10 PM

$PDSB Bro are you done? You lost money and I'm sorry for that, but spamming continuously won't fix anything

1 · Reply

Jennifer_1 Aug. 13 at 3:09 PM

$PDSB picking up a bit

0 · Reply

Mr_Charlie Aug. 13 at 2:24 PM

$PDSB Frank will live from this until Jan when company will be delisted and funds over. Such a criminal.

0 · Reply

Market Cap	12.33M
Revenue (ttm)	0.00
Net Income (ttm)	-34.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.21

Volume	1,038,600
Avg Vol	1,237,224
Day's Range	N/A - N/A
Shares Out	55.92M
Stochastic %K	0%
Beta	1.62
Analysts	Strong Sell
Price Target	$4.83